Home / Michael J. Cerminaro

Michael J. Cerminaro

Board of Directors
Michael J. Cerminaro,
President & COO

mike@thrombolex.com

Mr. Cerminaro leads the capital formation process while sharing the strategic management for the Company with Mr. Woodall. He is responsible for legal, finance & accounting, sales & marketing, and manufacturing activities of the company.

 

He has extensive experience in early stage company development, as well as, private equity leadership. Mr. Cerminaro is the founder of the Cerminaro Group, a private equity advisory and principal investment group, where he serves as the President and CEO.

 

He was a co-founder of Sound Harbor Partners, a private credit management firm with over $2 billion of assets under management that he successfully exited. He was one of the original senior partners who built and developed BlackRock Private Equity Partners (PEP), a $5 billion global private equity investment platform. While at BlackRock PEP he served as the Chairman of the Investment Operating Committee, Chairman of the Investment Valuation Committee, and as a member of the Management Committee.

 

He was also a co-founding member of the private equity advisory platforms of UBS Warburg and Bank of America Capital Markets. Mr. Cerminaro has been an angel investor in numerous start-ups and has served on the board of directors for a number of early stage companies as well as the advisory boards of several leading private equity firms in the US and in Europe.

 

He received his undergraduate degree with a double major in Economics and Business Administration from the State University of New York at Brockport and received an MBA in Finance from the Mays Business School at Texas A&M University.

Opportunity

“ It’s an opportunity for us to do something that’s going to have a materially positive impact on the healthcare system and help people.” 

                               

                   -  Mike Cerminaro

                        President and COO

Available Now:
Need more details? Contact us.

We are here to assist. Contact us by phone, email or via our social media channels.

CONTACT US
BASHIR_2018_Logo_Full_Color-stacked.jpg

The BASHIR™

Endovascular Catheter is intended for the controlled and selective infusion of physician­ specified fluids, including thrombolytics, into the peripheral vasculature, enabling the restoration of blood flow in patients with venous thrombus.

The BASHIR™ Plus

Endovascular Catheter 

is intended for the controlled and selective infusion of physician­ specified fluids, including thrombolytics, into the peripheral vasculature, enabling the restoration of blood flow in patients with venous thrombus.

The BASHIR™ +30

Endovascular Catheter 

is intended for the controlled and selective infusion of physician­ specified fluids, including thrombolytics, into the peripheral vasculature, enabling the restoration of blood flow in patients with venous thrombus.

The BASHIR™ N-X

Endovascular Catheter is a device intended for the localized infusion of physician-specified fluids, into the peripheral vasculature, including the pulmonary arteries.

BASHIR_PLUS10_Full_Color.jpg

The BASHIR™ +10

Endovascular Catheter 

is intended for the controlled and selective infusion of physician­ specified fluids, including thrombolytics, into the peripheral vasculature, enabling the restoration of blood flow in patients with venous thrombus.

The BASHIR™ +40

Endovascular Catheter 

is intended for the controlled and selective infusion of physician­ specified fluids, including thrombolytics, into the peripheral vasculature, enabling the restoration of blood flow in patients with venous thrombus.

The BASHIR™ S-B

Endovascular Catheter is a device intended for the localized infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature.

The BASHIR™ +20

Endovascular Catheter 

is intended for the controlled and selective infusion of physician­ specified fluids, including thrombolytics, into the peripheral vasculature, enabling the restoration of blood flow in patients with venous thrombus.